Pair Name	Bufalin, Hydroxycamptothecin
Disease Info	[ICD-11: 2C82]	Prostate cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL-xL	hsa598
	Up-regulation	Expression	GSK3B	hsa2932
	Up-regulation	Expression	PDCD4	hsa27250
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	DU145	Prostate carcinoma	Homo sapiens (Human)	CVCL_0105
In Vivo Model	Cell suspensions of DU 145 cells in the logarithmic growth phase were prepared at a concentration of 1×10⁷ cells/ml, using physiological saline.
Result	The present study suggested that the combination of bufalin and hydroxycampothecin improved the inhibitory effects of both drugs on CRPC tumors in vivo, potentially via the regulation of the PI3K/AKT/GSK-3β and p53-dependent apoptosis signaling pathways.